Charles Williams Sells 2,036 Shares of Surrozen (NASDAQ:SRZN) Stock

Surrozen, Inc. (NASDAQ:SRZN) COO Charles Williams sold 2,036 shares of the firm’s stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $33.33, for a total value of $67,859.88. Following the completion of the sale, the chief operating officer directly owned 16,571 shares in the company, valued at approximately $552,311.43. The trade was a 10.94% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this link.

Surrozen Trading Up 4.6%

Shares of SRZN opened at $34.13 on Thursday. Surrozen, Inc. has a 12 month low of $5.90 and a 12 month high of $35.00. The stock’s 50 day moving average is $28.42 and its two-hundred day moving average is $22.26. The firm has a market cap of $392.15 million, a P/E ratio of -1.02 and a beta of 0.59.

Surrozen (NASDAQ:SRZN) last issued its quarterly earnings data on Monday, March 23rd. The company reported ($7.59) EPS for the quarter, missing the consensus estimate of ($1.29) by ($6.30). Surrozen had a negative net margin of 7,476.67% and a negative return on equity of 4,055.04%. The business had revenue of $0.53 million during the quarter, compared to analyst estimates of $0.66 million. Equities research analysts forecast that Surrozen, Inc. will post -4.04 EPS for the current year.

Institutional Trading of Surrozen

A number of institutional investors have recently made changes to their positions in SRZN. Millennium Management LLC boosted its stake in shares of Surrozen by 557.1% in the fourth quarter. Millennium Management LLC now owns 721,266 shares of the company’s stock worth $16,301,000 after acquiring an additional 611,497 shares during the last quarter. Spruce Street Capital LP acquired a new stake in shares of Surrozen in the fourth quarter worth approximately $9,764,000. Kalehua Capital Management LLC acquired a new stake in shares of Surrozen in the fourth quarter worth approximately $8,705,000. Braidwell LP lifted its position in Surrozen by 235.7% during the fourth quarter. Braidwell LP now owns 470,000 shares of the company’s stock worth $10,622,000 after buying an additional 330,000 shares in the last quarter. Finally, Balyasny Asset Management L.P. lifted its position in Surrozen by 169.3% during the fourth quarter. Balyasny Asset Management L.P. now owns 190,489 shares of the company’s stock worth $4,305,000 after buying an additional 119,757 shares in the last quarter. 66.57% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

SRZN has been the topic of several research analyst reports. Cantor Fitzgerald reissued an “overweight” rating and issued a $40.00 price objective on shares of Surrozen in a report on Tuesday, March 24th. TD Cowen began coverage on Surrozen in a report on Tuesday, April 21st. They issued a “buy” rating on the stock. Wall Street Zen raised Surrozen from a “sell” rating to a “hold” rating in a research note on Saturday, March 28th. HC Wainwright reaffirmed a “buy” rating and issued a $36.00 price target (up from $32.00) on shares of Surrozen in a research note on Tuesday, March 24th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Surrozen in a research note on Tuesday, April 21st. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Surrozen has an average rating of “Moderate Buy” and an average price target of $38.00.

Trending Headlines about Surrozen

Here are the key news stories impacting Surrozen this week:

• Positive Sentiment: Management reiterated a development timeline: Surrozen remains on track to file an IND for lead ophthalmic candidate SZN‑8141 in the second half of 2026 — a clear clinical catalyst if met. Surrozen Reports First Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: Balance sheet supports near-term development: cash and equivalents of $106.9M as of March 31, 2026 should fund operations and the planned IND work, reducing immediate financing risk. Surrozen Reports First Quarter 2026 Financial Results and Provides Business Update
• Neutral Sentiment: Revenue slightly beat expectations ($5.0M vs. $4.0M consensus), but revenue remains small relative to expenses — notable as validation of some commercial activity, but not yet material to profitability. Press Release
• Neutral Sentiment: Analyst coverage remains mixed but generally favorable (consensus “Moderate Buy” and average target near $38) — external expectations could support upside if clinical milestones are met. MarketBeat SRZN Coverage
• Negative Sentiment: Severe earnings miss: reported EPS of ($11.65) vs. consensus ($1.09) — the gap likely reflects one‑time items or noncash charges but drove an extremely negative net margin and ROE, increasing short‑term volatility and investor concern about accounting/expense trajectory. Press Release
• Negative Sentiment: Insider selling: recent sales by the CEO, COO and a VP (multiple SEC filings) reduce insider ownership by notable percentages — this can be interpreted negatively by some investors even if sales are routine or for diversification. Insider Selling: Surrozen (NASDAQ:SRZN) VP Sells 1,584 Shares of Stock

About Surrozen

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.